Lifecore Biomedical, Inc. \De\ (LFCR) Stock Price & Analysis
Lifecore Biomedical, Inc. \De\ (LFCR) rose 1.62% to USD 5.66 as of June 10, 2026 at 03:28 UTC, according to Nexqual real-time market data.
LFCR last closed at USD 5.57; the session ranged USD 5.39–5.73 on volume of 162,824 shares. Market capitalization is $212.30M, with a 52-week range of USD 3.63–8.98 (NMS). Source: Nexqual, June 10, 2026 at 03:28 UTC.
Key Statistics (as of June 10, 2026 at 03:28 UTC)
| Price | USD 5.66 |
|---|---|
| Change | ▲ 1.62% (up) |
| Previous Close | USD 5.57 |
| Open | USD 5.5 |
| Day Range | USD 5.39 – 5.73 |
| 52-Week Range | USD 3.63 – 8.98 |
| Volume | 162,824 shares |
| Market Cap | $212.30M |
| Exchange | NMS |
Technical Analysis (LFCR)
Nexqual's technical model rates LFCR "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:28 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.64 (neutral) |
| vs SMA50 | Above (USD 4.86) |
| MACD | 0.21 (positive) |
Analyst Ratings (LFCR)
Wall Street analysts rate LFCR "None" based on 3 analysts, with a mean price target of USD 6.67 (range USD 5–9), per Nexqual as of June 10, 2026 at 03:28 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 6.67 |
| High Target | USD 9 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (LFCR)
| Next Earnings Date | 2026-08-05 |
|---|---|
| Revenue Estimate | $32.02M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.43 vs est -0.3 ▼ miss |
| 2025-12-31 | USD -0.16 vs est -0.16 ▲ beat |
| 2025-02-28 | USD -0.47 vs est -0.15 ▼ miss |
| 2024-11-30 | USD -0.25 vs est -0.29 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Financials & Fundamentals (LFCR)
| Total Revenue | $129.46M |
|---|---|
| Gross Margin | +31.37% |
| Operating Margin | -13.25% |
| Profit Margin | -23.78% |
| Debt / Equity | 722.6 |
| Current Ratio | 3.49 |
| Total Cash | $20.80M |
| Total Debt | $150.14M |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Financial Health Score (LFCR)
Nexqual rates Lifecore Biomedical, Inc. \De\'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:28 UTC.
| Growth | Critical — Revenue -41% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Gross margin 31%, operating -13% |
| Balance Sheet | Weak — $21M cash vs $150M debt |
| Cash Flow | Solid — Operating cash flow $13M |
| Efficiency | Mixed — No data |
Ownership (LFCR)
| Insider Ownership | +2.76% |
|---|---|
| Institutional Ownership | +77.19% |
| Shares Outstanding | 37.51M |
| Float | 19.62M |
| Short % of Float | +7.72% |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Leadership (LFCR)
Lifecore Biomedical, Inc. \De\ is led by Paul Josephs (age 59), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:28 UTC.
| President, CEO & Director | Paul Josephs (age 59) |
|---|---|
| Executive VP & CFO | Ryan D. Lake (age 48) |
| Senior Vice President of Operations | Thomas Guldager |
| Director of Internal Audit & Chief Compliance Officer | Aaron Perlitsh |
| Executive Vice President of Quality & Development Services | Jackie Q. Klecker |
Major Backers & Investors (LFCR)
Notable institutional backers of Lifecore Biomedical, Inc. \De\ include WYNNEFIELD CAPITAL INC, Legion Partners Asset Management, LLC, Greenhaven Road Investment Management, L.p., according to Nexqual as of June 10, 2026 at 03:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| WYNNEFIELD CAPITAL INC | 12.54% |
| Legion Partners Asset Management, LLC | 11.9% |
| Greenhaven Road Investment Management, L.p. | 9.43% |
| 325 Capital Llc | 5.77% |
| Grizzlyrock Capital, LLC | 2.21% |
| Morgan Stanley | 2.04% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.32% |
| Vanguard Group | 7.16% |
| Geode Capital | 2.17% |
| State Street | 1.71% |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
From Lifecore Biomedical, Inc. \De\'s Latest SEC 10-K Filing (filed 2025-08-07)
Key Strengths & Strategy (as disclosed to the SEC)
- Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally.
- It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
- The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications.
- In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHVS | Pharvaris N.V. | USD 31.6 | ▲ 1.64% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 2.19 | ▲ 1.86% |
| SABS | SAB Biotherapeutics, Inc. | USD 3.36 | ▼ 0.59% |
| ZURA | Zura Bio Limited | USD 3.69 | ▲ 8.53% |
| SERA | Sera Prognostics, Inc. | USD 2.13 | ▼ 6.99% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:28 UTC. This page is informational and not investment advice.